Unit of Metabolic and Autoimmune Liver Diseases, Pediatric Hospital Bambino Gesù, IRCCS, Square S. Onofrio 4, 00165, Rome, Italy.
J Gastroenterol. 2012 Jan;47(1):29-36. doi: 10.1007/s00535-011-0467-x. Epub 2011 Oct 8.
Nonalcoholic fatty liver disease encompasses a spectrum of disease from asymptomatic steatosis, with or without elevated aminotransferases, to cirrhosis with relative complications and hepatocellular carcinoma. Owing to the increasing prevalence of nonalcoholic fatty liver disease and the potential for nonalcoholic steatohepatitis to progress to cirrhosis and liver-related mortality, more research has been focused on therapy of this important liver disease over the last two decades. To date, weight loss and physical activity represent the cornerstone of treatment, with interventions being limited to subjects at risk of disease progression, but the type of treatment remains a matter of debate. A few medications have shown promising results in preliminary pilot studies, but few agents have been tested rigorously. Today, multiple therapeutic approaches are considered the way to go in treating nonalcoholic steatohepatitis patients. In this paper we review the status of current and emerging therapeutic strategies for children and adult patients with nonalcoholic steatohepatitis.
非酒精性脂肪性肝病涵盖了一系列疾病,从无症状性脂肪变性(伴或不伴氨基转移酶升高),到肝硬化伴相关并发症和肝细胞癌。由于非酒精性脂肪性肝病的患病率不断增加,以及非酒精性脂肪性肝炎进展为肝硬化和与肝脏相关的死亡率的可能性,过去二十年,人们更加关注这种重要肝病的治疗方法。迄今为止,减轻体重和增加体力活动是非酒精性脂肪性肝病治疗的基石,干预措施仅限于有疾病进展风险的患者,但治疗的类型仍然存在争议。少数药物在初步的试点研究中显示出了有希望的结果,但很少有药物经过严格的测试。目前,多种治疗方法被认为是治疗非酒精性脂肪性肝炎患者的方法。本文综述了目前和新兴的治疗策略在儿童和成年非酒精性脂肪性肝炎患者中的应用。